Real-World Hemoglobin A1C (HbA1c) Following Initiation of the Omnipod 5 Automated Insulin Delivery System
Authors' conclusion
In a real-world setting, Omnipod 5 was associated with reduced HbA1c and an increased proportion of individuals achieving ADA and HEDIS glycemic targets.
Study context
- Population
- Individuals with T1D or T2D initiating Omnipod 5 Automated Insulin Delivery (AID), commercial and Medicare Advantage enrollees, Optum Research Database, Aug 2021–Dec 2023; mean age 54 years, 90% prior CGM, 64% prior pump792 with pre/post HbA1c
- Participants
- 2,504 individuals
- Exposure
- HbA1c pre- vs post-initiation of Omnipod 5
- Outcome
- HbA1c change after initiating Omnipod 5
Methodological detailsclaims data, pre-post comparison
- Claims data
- Pre-post comparison
Main finding
As reported in the abstract
Change in HbA1c
Mean reduction in HbA1c (P < 0.001)
0.4%
Observational data: associations, not effects.
Further findings
Achieved ADA target HbA1c <7%
increase 13% · P < 0.001
Achieved HEDIS target HbA1c <8%
increase 16% · P < 0.001
Change in HbA1c by diabetes type
- Mean reduction, T1D
- 0.4%
- Mean reduction, T2D
- 0.5%
Change in HbA1c, pre-initiation HbA1c ≥9% (n=135)
- Reduction (P < 0.001)
- 1.4%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System. Diabetes Technol Ther. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →